Gastric neuroendocrine tumor presenting with carcinoid syndrome
We present an interesting case of a patient with carcinoid syndrome as a late manifestation of a gastric neuroendocrine tumor with, highlighting the importance of knowing how to identify the carcinoid syndrome.PMID:38634903 | DOI:10.17235/reed.2024.10364/2024 (Source: Revista Espanola de Enfermedades Digestivas)
Source: Revista Espanola de Enfermedades Digestivas - April 18, 2024 Category: Gastroenterology Authors: Lu ís Miguel Relvas T ânia Gago Francisco Velasco S ónia Barros Isabel Carvalho Bruno Peixe Source Type: research
Perioperative management of a double valve replacement and coronary artery bypass graft in a patient with carcinoid syndrome; a case report and literature review
CONCLUSION: No carcinoid crisis was evident perioperatively. High vigilance with appropriate monitoring, aggressive management combined with meticulous choice of pharmaceutical agents led to this outcome.PMID:38626318 | DOI:10.1177/02676591241247977 (Source: Perfusion)
Source: Perfusion - April 16, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Despoina G Sarridou Anna Gkiouliava Helena Argiriadou Sophia Anastasia Mouratoglou Jeremy B Mitchell Christopher P Walker Source Type: research
Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope
World J Gastroenterol. 2024 Mar 28;30(12):1670-1675. doi: 10.3748/wjg.v30.i12.1670.ABSTRACTThis editorial highlights the remarkable advancements in medical treatment strategies for pancreatic neuroendocrine tumors (pan-NETs), emphasizing tailored approaches for specific subtypes. Cytoreductive surgery and somatostatin analogs (SSAs) play pivotal roles in managing tumors, while palliative options such as molecular targeted therapy, peptide receptor radionuclide therapy, and chemotherapy are reserved for SSA-refractory patients. Gastrinomas, insulinomas, glucagonomas, carcinoid tumors and VIPomas necessitate distinct thera-p...
Source: World Journal of Gastroenterology : WJG - April 15, 2024 Category: Gastroenterology Authors: Somdatta Giri Jayaprakash Sahoo Source Type: research
Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope
World J Gastroenterol. 2024 Mar 28;30(12):1670-1675. doi: 10.3748/wjg.v30.i12.1670.ABSTRACTThis editorial highlights the remarkable advancements in medical treatment strategies for pancreatic neuroendocrine tumors (pan-NETs), emphasizing tailored approaches for specific subtypes. Cytoreductive surgery and somatostatin analogs (SSAs) play pivotal roles in managing tumors, while palliative options such as molecular targeted therapy, peptide receptor radionuclide therapy, and chemotherapy are reserved for SSA-refractory patients. Gastrinomas, insulinomas, glucagonomas, carcinoid tumors and VIPomas necessitate distinct thera-p...
Source: World Journal of Gastroenterology - April 15, 2024 Category: Gastroenterology Authors: Somdatta Giri Jayaprakash Sahoo Source Type: research
Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope
World J Gastroenterol. 2024 Mar 28;30(12):1670-1675. doi: 10.3748/wjg.v30.i12.1670.ABSTRACTThis editorial highlights the remarkable advancements in medical treatment strategies for pancreatic neuroendocrine tumors (pan-NETs), emphasizing tailored approaches for specific subtypes. Cytoreductive surgery and somatostatin analogs (SSAs) play pivotal roles in managing tumors, while palliative options such as molecular targeted therapy, peptide receptor radionuclide therapy, and chemotherapy are reserved for SSA-refractory patients. Gastrinomas, insulinomas, glucagonomas, carcinoid tumors and VIPomas necessitate distinct thera-p...
Source: World Journal of Gastroenterology : WJG - April 15, 2024 Category: Gastroenterology Authors: Somdatta Giri Jayaprakash Sahoo Source Type: research
Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope
World J Gastroenterol. 2024 Mar 28;30(12):1670-1675. doi: 10.3748/wjg.v30.i12.1670.ABSTRACTThis editorial highlights the remarkable advancements in medical treatment strategies for pancreatic neuroendocrine tumors (pan-NETs), emphasizing tailored approaches for specific subtypes. Cytoreductive surgery and somatostatin analogs (SSAs) play pivotal roles in managing tumors, while palliative options such as molecular targeted therapy, peptide receptor radionuclide therapy, and chemotherapy are reserved for SSA-refractory patients. Gastrinomas, insulinomas, glucagonomas, carcinoid tumors and VIPomas necessitate distinct thera-p...
Source: World Journal of Gastroenterology - April 15, 2024 Category: Gastroenterology Authors: Somdatta Giri Jayaprakash Sahoo Source Type: research
Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope
World J Gastroenterol. 2024 Mar 28;30(12):1670-1675. doi: 10.3748/wjg.v30.i12.1670.ABSTRACTThis editorial highlights the remarkable advancements in medical treatment strategies for pancreatic neuroendocrine tumors (pan-NETs), emphasizing tailored approaches for specific subtypes. Cytoreductive surgery and somatostatin analogs (SSAs) play pivotal roles in managing tumors, while palliative options such as molecular targeted therapy, peptide receptor radionuclide therapy, and chemotherapy are reserved for SSA-refractory patients. Gastrinomas, insulinomas, glucagonomas, carcinoid tumors and VIPomas necessitate distinct thera-p...
Source: World Journal of Gastroenterology : WJG - April 15, 2024 Category: Gastroenterology Authors: Somdatta Giri Jayaprakash Sahoo Source Type: research
Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope
World J Gastroenterol. 2024 Mar 28;30(12):1670-1675. doi: 10.3748/wjg.v30.i12.1670.ABSTRACTThis editorial highlights the remarkable advancements in medical treatment strategies for pancreatic neuroendocrine tumors (pan-NETs), emphasizing tailored approaches for specific subtypes. Cytoreductive surgery and somatostatin analogs (SSAs) play pivotal roles in managing tumors, while palliative options such as molecular targeted therapy, peptide receptor radionuclide therapy, and chemotherapy are reserved for SSA-refractory patients. Gastrinomas, insulinomas, glucagonomas, carcinoid tumors and VIPomas necessitate distinct thera-p...
Source: World Journal of Gastroenterology - April 15, 2024 Category: Gastroenterology Authors: Somdatta Giri Jayaprakash Sahoo Source Type: research
Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope
World J Gastroenterol. 2024 Mar 28;30(12):1670-1675. doi: 10.3748/wjg.v30.i12.1670.ABSTRACTThis editorial highlights the remarkable advancements in medical treatment strategies for pancreatic neuroendocrine tumors (pan-NETs), emphasizing tailored approaches for specific subtypes. Cytoreductive surgery and somatostatin analogs (SSAs) play pivotal roles in managing tumors, while palliative options such as molecular targeted therapy, peptide receptor radionuclide therapy, and chemotherapy are reserved for SSA-refractory patients. Gastrinomas, insulinomas, glucagonomas, carcinoid tumors and VIPomas necessitate distinct thera-p...
Source: World Journal of Gastroenterology : WJG - April 15, 2024 Category: Gastroenterology Authors: Somdatta Giri Jayaprakash Sahoo Source Type: research
Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope
World J Gastroenterol. 2024 Mar 28;30(12):1670-1675. doi: 10.3748/wjg.v30.i12.1670.ABSTRACTThis editorial highlights the remarkable advancements in medical treatment strategies for pancreatic neuroendocrine tumors (pan-NETs), emphasizing tailored approaches for specific subtypes. Cytoreductive surgery and somatostatin analogs (SSAs) play pivotal roles in managing tumors, while palliative options such as molecular targeted therapy, peptide receptor radionuclide therapy, and chemotherapy are reserved for SSA-refractory patients. Gastrinomas, insulinomas, glucagonomas, carcinoid tumors and VIPomas necessitate distinct thera-p...
Source: World Journal of Gastroenterology - April 15, 2024 Category: Gastroenterology Authors: Somdatta Giri Jayaprakash Sahoo Source Type: research
Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope
World J Gastroenterol. 2024 Mar 28;30(12):1670-1675. doi: 10.3748/wjg.v30.i12.1670.ABSTRACTThis editorial highlights the remarkable advancements in medical treatment strategies for pancreatic neuroendocrine tumors (pan-NETs), emphasizing tailored approaches for specific subtypes. Cytoreductive surgery and somatostatin analogs (SSAs) play pivotal roles in managing tumors, while palliative options such as molecular targeted therapy, peptide receptor radionuclide therapy, and chemotherapy are reserved for SSA-refractory patients. Gastrinomas, insulinomas, glucagonomas, carcinoid tumors and VIPomas necessitate distinct thera-p...
Source: World Journal of Gastroenterology : WJG - April 15, 2024 Category: Gastroenterology Authors: Somdatta Giri Jayaprakash Sahoo Source Type: research
Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope
World J Gastroenterol. 2024 Mar 28;30(12):1670-1675. doi: 10.3748/wjg.v30.i12.1670.ABSTRACTThis editorial highlights the remarkable advancements in medical treatment strategies for pancreatic neuroendocrine tumors (pan-NETs), emphasizing tailored approaches for specific subtypes. Cytoreductive surgery and somatostatin analogs (SSAs) play pivotal roles in managing tumors, while palliative options such as molecular targeted therapy, peptide receptor radionuclide therapy, and chemotherapy are reserved for SSA-refractory patients. Gastrinomas, insulinomas, glucagonomas, carcinoid tumors and VIPomas necessitate distinct thera-p...
Source: World Journal of Gastroenterology - April 15, 2024 Category: Gastroenterology Authors: Somdatta Giri Jayaprakash Sahoo Source Type: research
Surgical outcomes for non ‐small cell lung cancer in younger adults: A population‐based study
ConclusionsOverall, younger patients with NSCLC treated surgically exhibit superior OS and LCSS compared to their older counterparts, although no statistically significant difference in LCSS for stages III –IV was observed between the two age groups. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 13, 2024 Category: Cancer & Oncology Authors: Zhirong Zhang,
Huandong Huo,
Feng Li,
Jinbai Miao,
Bin Hu,
Shuo Chen Tags: ORIGINAL ARTICLE Source Type: research
